Comparative Pharmacology
Head-to-head clinical analysis: ZOFRAN ODT versus ZOFRAN PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ZOFRAN ODT versus ZOFRAN PRESERVATIVE FREE.
ZOFRAN ODT vs ZOFRAN PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective antagonist of serotonin 5-HT3 receptors, blocking serotonin binding in the chemoreceptor trigger zone and gastrointestinal tract, thereby inhibiting emesis.
Selective 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone (CTZ) and gastrointestinal tract, inhibiting emetic reflex.
8 mg orally disintegrating tablet (ODT) 30 minutes before chemotherapy; for prevention of nausea/vomiting, 8 mg orally twice daily.
4-8 mg intravenously or intramuscularly as a single dose for prevention of chemotherapy-induced nausea and vomiting; 8 mg orally 30 minutes before chemotherapy, repeated every 8-12 hours as needed.
None Documented
None Documented
Terminal elimination half-life approximately 3–6 hours in adults; prolonged to 8–15 hours in patients with severe hepatic impairment (Child-Pugh C) due to reduced clearance.
Terminal elimination half-life is approximately 3-6 hours in adults, but may be prolonged to 15-20 hours in severe hepatic impairment (Child-Pugh class C).
Renal (47% as unchanged drug and metabolites, primarily glucuronide conjugates) and hepatic metabolism; about 25% excreted in feces; less than 10% excreted unchanged in urine.
Approximately 5% of ondansetron is excreted unchanged in urine; the remainder is extensively metabolized, with metabolites excreted in urine (46-60%) and feces (22-29%).
Category C
Category C
Antiemetic (5-HT3 Antagonist)
Antiemetic (5-HT3 Antagonist)